BACKGROUND: Determining cervical precancer risk among human immunodeficiency virus (HIV)-infected women who despite a normal Pap test are positive for oncogenic human papillomavirus (oncHPV) types is important for setting screening practices. METHODS: A total of 2791 HIV-infected and 975 HIV-uninfected women in the Women's Interagency HIV Study were followed semiannually with Pap tests and colposcopy. Cumulative risks of cervical intraepithelial neoplasia grade 2 or greater (CIN-2+; threshold used for CIN treatment) and grade 3 or greater (CIN-3+; threshold to set screening practices) were measured in HIV-infected and HIV-uninfected women with normal Pap tests, stratified by baseline HPV results, and also in HIV-infected women with a low-grade squamous intraepithelial lesion (LSIL; benchmark indication for colposcopy). RESULTS: At baseline, 1021 HIV-infected and 518 HIV-uninfected women had normal Pap tests, of whom 154 (15%) and 27 (5%), respectively, tested oncHPV positive. The 5-year CIN-2+ cumulative risk in the HIV-infected oncHPV-positive women was 22% (95% confidence interval [CI], 9%-34%), 12% (95% CI, 0%-22%), and 14% (95% CI, 2%-25%) among those with CD4 counts <350, 350-499, and ≥500 cells/µL, respectively, whereas it was 10% (95% CI, 0%-21%) in those without HIV. For CIN-3+, the cumulative risk averaged 4% (95% CI, 1%-8%) in HIV-infected oncHPV-positive women, and 10% (95% CI, 0%-23%) among those positive for HPV type 16. In HIV-infected women with LSIL, CIN-3+ risk was 7% (95% CI, 3%-11%). In multivariate analysis, HIV-infected HPV16-positive women had 13-fold (P = .001) greater CIN-3+ risk than oncHPV-negative women (referent), and HIV-infected women with LSIL had 9-fold (P < .0001) greater risk. CONCLUSIONS: HIV-infected women with a normal Pap result who test HPV16 positive have high precancer risk (similar to those with LSIL), possibly warranting immediate colposcopy. Repeat screening in 1 year may be appropriate if non-16 oncHPV is detected.
BACKGROUND: Determining cervical precancer risk among human immunodeficiency virus (HIV)-infected women who despite a normal Pap test are positive for oncogenic human papillomavirus (oncHPV) types is important for setting screening practices. METHODS: A total of 2791 HIV-infected and 975 HIV-uninfected women in the Women's Interagency HIV Study were followed semiannually with Pap tests and colposcopy. Cumulative risks of cervical intraepithelial neoplasia grade 2 or greater (CIN-2+; threshold used for CIN treatment) and grade 3 or greater (CIN-3+; threshold to set screening practices) were measured in HIV-infected and HIV-uninfected women with normal Pap tests, stratified by baseline HPV results, and also in HIV-infected women with a low-grade squamous intraepithelial lesion (LSIL; benchmark indication for colposcopy). RESULTS: At baseline, 1021 HIV-infected and 518 HIV-uninfected women had normal Pap tests, of whom 154 (15%) and 27 (5%), respectively, tested oncHPV positive. The 5-year CIN-2+ cumulative risk in the HIV-infected oncHPV-positive women was 22% (95% confidence interval [CI], 9%-34%), 12% (95% CI, 0%-22%), and 14% (95% CI, 2%-25%) among those with CD4 counts <350, 350-499, and ≥500 cells/µL, respectively, whereas it was 10% (95% CI, 0%-21%) in those without HIV. For CIN-3+, the cumulative risk averaged 4% (95% CI, 1%-8%) in HIV-infected oncHPV-positive women, and 10% (95% CI, 0%-23%) among those positive for HPV type 16. In HIV-infected women with LSIL, CIN-3+ risk was 7% (95% CI, 3%-11%). In multivariate analysis, HIV-infected HPV16-positive women had 13-fold (P = .001) greater CIN-3+ risk than oncHPV-negative women (referent), and HIV-infected women with LSIL had 9-fold (P < .0001) greater risk. CONCLUSIONS: HIV-infected women with a normal Pap result who test HPV16 positive have high precancer risk (similar to those with LSIL), possibly warranting immediate colposcopy. Repeat screening in 1 year may be appropriate if non-16 oncHPV is detected.
Authors: Melanie C Bacon; Viktor von Wyl; Christine Alden; Gerald Sharp; Esther Robison; Nancy Hessol; Stephen Gange; Yvonne Barranday; Susan Holman; Kathleen Weber; Mary A Young Journal: Clin Diagn Lab Immunol Date: 2005-09
Authors: Warner K Huh; Kevin A Ault; David Chelmow; Diane D Davey; Robert A Goulart; Francisco A R Garcia; Walter K Kinney; L Stewart Massad; Edward J Mayeaux; Debbie Saslow; Mark Schiffman; Nicolas Wentzensen; Herschel W Lawson; Mark H Einstein Journal: Obstet Gynecol Date: 2015-02 Impact factor: 7.661
Authors: Howard D Strickler; Robert D Burk; Melissa Fazzari; Kathryn Anastos; Howard Minkoff; L Stewart Massad; Charles Hall; Melanie Bacon; Alexandra M Levine; D Heather Watts; Michael J Silverberg; Xiaonan Xue; Nicolas F Schlecht; Sandra Melnick; Joel M Palefsky Journal: J Natl Cancer Inst Date: 2005-04-20 Impact factor: 13.506
Authors: Tiffany G Harris; Robert D Burk; Joel M Palefsky; L Stewart Massad; Ji Yon Bang; Kathryn Anastos; Howard Minkoff; Charles B Hall; Melanie C Bacon; Alexandra M Levine; D Heather Watts; Michael J Silverberg; Xiaonan Xue; Sandra L Melnick; Howard D Strickler Journal: JAMA Date: 2005-03-23 Impact factor: 56.272
Authors: Diane Solomon; Diane Davey; Robert Kurman; Ann Moriarty; Dennis O'Connor; Marianne Prey; Stephen Raab; Mark Sherman; David Wilbur; Thomas Wright; Nancy Young Journal: JAMA Date: 2002-04-24 Impact factor: 56.272
Authors: Thomas C Wright; Mark H Stoler; Catherine M Behrens; Abha Sharma; Guili Zhang; Teresa L Wright Journal: Gynecol Oncol Date: 2015-01-08 Impact factor: 5.482
Authors: Nubia Muñoz; F Xavier Bosch; Silvia de Sanjosé; Rolando Herrero; Xavier Castellsagué; Keerti V Shah; Peter J F Snijders; Chris J L M Meijer Journal: N Engl J Med Date: 2003-02-06 Impact factor: 91.245
Authors: Howard D Strickler; Joel M Palefsky; Keerti V Shah; Kathryn Anastos; Robert S Klein; Howard Minkoff; Ann Duerr; L Stewart Massad; David D Celentano; Charles Hall; Melissa Fazzari; Susan Cu-Uvin; Melanie Bacon; Paula Schuman; Alexandra M Levine; Amanda J Durante; Stephen Gange; Sandra Melnick; Robert D Burk Journal: J Natl Cancer Inst Date: 2003-07-16 Impact factor: 13.506
Authors: Philip E Castle; Robert D Burk; Leslie S Massad; Isam-Eldin Eltoum; Charles B Hall; Nancy A Hessol; Kathryn Anastos; Xianhong Xie; Howard Minkoff; Xiaonan Xue; Gypsyamber D'Souza; Lisa Flowers; Christine Colie; Lisa Rahangdale; Margaret A Fischl; Joel M Palefsky; Howard D Strickler Journal: Int J Cancer Date: 2019-10-18 Impact factor: 7.396
Authors: Hilary A Robbins; Howard D Strickler; L Stewart Massad; Christopher B Pierce; Teresa M Darragh; Howard Minkoff; Marla J Keller; Margaret Fischl; Joel Palefsky; Lisa Flowers; Lisa Rahangdale; Joel Milam; Sadeep Shrestha; Christine Colie; Gypsyamber DʼSouza Journal: AIDS Date: 2017-04-24 Impact factor: 4.177
Authors: Philip E Castle; Brian Befano; Mark Schiffman; Nicolas Wentzensen; Thomas Lorey; Nancy Poitras; Marianne Hyer; Li C Cheung Journal: Prev Med Date: 2022-07-08 Impact factor: 4.637
Authors: Arti Barnes; Andrea C Betts; Eric K Borton; Joanne M Sanders; Sandi L Pruitt; Claudia Werner; Andres Bran; Carolee D Estelle; Bijal A Balasubramanian; Stephen J Inrig; Ethan A Halm; Celette Sugg Skinner; Jasmin A Tiro Journal: AIDS Date: 2018-08-24 Impact factor: 4.177
Authors: Marla J Keller; Robert D Burk; L Stewart Massad; Isam-Eldin Eltoum; Nancy A Hessol; Kathryn Anastos; Xianhong Xie; Howard Minkoff; Xiaonan Xue; Laura L Reimers; Mark Kuniholm; Gypsyamber DʼSouza; Christine Colie; Bradley Aouizerat; Joel M Palefsky; Howard D Strickler Journal: AIDS Date: 2018-11-28 Impact factor: 4.632
Authors: Howard D Strickler; Marla J Keller; Nancy A Hessol; Isam-Eldin Eltoum; Mark H Einstein; Philip E Castle; L Stewart Massad; Lisa Flowers; Lisa Rahangdale; Jessica M Atrio; Catalina Ramirez; Howard Minkoff; Adaora A Adimora; Igho Ofotokun; Christine Colie; Megan J Huchko; Margaret Fischl; Rodney Wright; Gypsyamber D'Souza; Jason Leider; Olga Diaz; Lorraine Sanchez-Keeland; Sadeep Shrestha; Xianhong Xie; Xiaonan Xue; Kathryn Anastos; Joel M Palefsky; Robert D Burk Journal: Clin Infect Dis Date: 2021-05-04 Impact factor: 9.079